Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,112 questions in 171 reviews · Eyes and Vision
current versionsNo studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Adherence · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 7 studies · 902 participants | Low |
Intervention NR Intraocular pressure · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 5 studies · 503 participants | Very low |
Intervention NR Visual field defects · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 4 studies · 301 participants | Very low |
Intervention NR Quality of life · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 3 studies · 265 participants | Very low |
Intervention NR Adverse effects · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 8 studies · 650 participants | Very low |
Intervention NR Persistence · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 1 study · 127 participants | Low |
Intervention NR Intraocular pressure · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 2 studies · 193 participants | Low |
Intervention NR Visual field defects · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient knowledge · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 4 studies · 390 participants | Low |
Intervention NR Adherence · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 8 studies · 650 participants | Very low |
Intervention NR Persistence · people with glaucoma or ocular hypertension Interventions for improving adherence to ocular hypotensive therapy (2013) · Cochrane | no estimate extracted | 3 studies · 265 participants | Very low |
Intervention NR Good functional vision (presenting visual acuity 6/12 or better) · people with age‐related cataract Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Poor visual outcome (best‐corrected visual acuity worse than 6/60) · people with age‐related cataract Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus… (2013) · Cochrane | OR 2.48 [0.74, 8.28] | 6 studies · 1250 participants | Very low |
Intervention NR Posterior capsule opacification 12 months after surgery · people with age‐related cataract Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus… (2013) · Cochrane | no estimate extracted | 2 studies · 494 participants | Very low |
Intervention NR Other complications · people with age‐related cataract Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · people with age‐related cataract Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · people with age‐related cataract Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Visual impairment · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | no estimate extracted | 2 studies · 354 participants | Ungraded |
Intervention NR Punctate keratitis · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.33 [0.22, 0.49] | 1 study · 551 participants | Moderate |
Intervention NR Sclerosing keratitis · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.74 [0.52, 1.06] | 1 study · 560 participants | Low |
Intervention NR Iridocyclitis · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.62 [0.43, 0.9] | 1 study · 554 participants | Moderate |
Intervention NR Chorioretinitis · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 1.75 [0.91, 3.37] | 1 study · 528 participants | Low |
Intervention NR Optic nerve disease · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.78 [0.57, 1.06] | 2 studies · 3577 participants | Low |
Intervention NR Visual field loss · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Punctate keratitis · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | no estimate extracted | 0 studies · 2 participants | Ungraded |
Intervention NR Sclerosing keratitis · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.06 [0, 1.23] | 1 study · 39 participants | Low |
Intervention NR Iridocyclitis · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | no estimate extracted | 0 studies · 2 participants | Ungraded |
Intervention NR Chorioretinitis · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.02 [0, 0.32] | 1 study · 200 participants | Moderate |
Intervention NR Optic nerve disease · people infected with O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | no estimate extracted | 2 studies · 354 participants | Ungraded |
Intervention NR Visual impairment · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 1.08 [0.33, 3.5] | 1 study · 485 participants | Very low |
Intervention NR Visual field loss · people living in communities affected by O.volvulus Ivermectin for onchocercal eye disease (river blindness) (2012) · Cochrane | RR 0.6 [0.41, 0.89] | 1 study · 636 participants | High |
Intervention NR Surgical failure (intraocular pressure >21mmHg) ( · patients with glaucoma surgery Beta radiation for glaucoma surgery (2012) · Cochrane | RR 0.23 [0.14, 0.4] | 4 studies · 561 participants | Moderate |
Intervention NR Intraocular pressure ( · patients with glaucoma surgery Beta radiation for glaucoma surgery (2012) · Cochrane | no estimate extracted | 2 studies · 123 participants | Low |
Intervention NR Adverse effect: cataract · patients with glaucoma surgery Beta radiation for glaucoma surgery (2012) · Cochrane | RR 1.79 [0.62, 5.14] | 3 studies · 423 participants | Moderate |
Sublingual immunotherapy vs placebo Total ocular symptom scores Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 36 studies · 3399 participants | Moderate |
Sublingual immunotherapy vs placebo Itchy/Gritty eyes Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 28 studies · 3020 participants | Moderate |
Sublingual immunotherapy vs placebo Watery eyes Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 21 studies · 2641 participants | Moderate |
Sublingual immunotherapy vs placebo Red eyes Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 20 studies · 1211 participants | Moderate |
Sublingual immunotherapy vs placebo Eye drops Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 13 studies · 1038 participants | Moderate |
Sublingual immunotherapy vs placebo Combined symptom‐medication scores Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 3 studies · 351 participants | Moderate |
Sublingual immunotherapy vs placebo Conjunctival immediate allergen sensitivity Symptom scores · patients with allergic conjunctivitis Sublingual immunotherapy for treating allergic conjunctivitis (2011) · Cochrane | no estimate extracted | 4 studies · 250 participants | Moderate |
Orientation & Mobility training vs physical exercise Total score (using structured skills assessment) · patients with adults with low vision Orientation and mobility training for adults with low vision (2010) · Cochrane | no estimate extracted | 2 studies · 67 participants | Very low |
Intervention NR Visual loss of 2+ lines at 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration (2009) · Cochrane | RR 0.96 [0.84, 1.09] | 2 studies · 715 participants | High |
Intervention NR Visual gain of 2+ lines at 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration (2009) · Cochrane | RR 1.06 [0.75, 1.5] | 2 studies · 715 participants | Low |
Intervention NR Contrast threshold loss ‐0.15 log units or more at 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration (2009) · Cochrane | RR 0.8 [0.63, 1.02] | 2 studies · 689 participants | Moderate |
Intervention NR Reading speed 40 word/minute or more after 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration (2009) · Cochrane | RR 0.88 [0.64, 1.2] | 2 studies · 692 participants | High |
Intervention NR Loss of 6+ points of overall NEI‐VFQ score at 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration (2009) · Cochrane | RR 1.35 [1.09, 1.68] | 2 studies · 689 participants | Low |
Intervention NR Adverse events: cataract surgery at 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration (2009) · Cochrane | RR 8.69 [4.06, 18.61] | 2 studies · 632 participants | High |